Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Peptide receptors as cancer drug targets.

Moody TW.

Ann N Y Acad Sci. 2019 May 10. doi: 10.1111/nyas.14100. [Epub ahead of print] Review.

PMID:
31074514
2.

PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Moody TW, Lee L, Iordanskaia T, Ramos-Alvarez I, Moreno P, Boudreau HE, Leto TL, Jensen RT.

Peptides. 2018 Sep 28. pii: S0196-9781(18)30174-8. doi: 10.1016/j.peptides.2018.09.005. [Epub ahead of print]

PMID:
30273693
3.

Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Moody TW, Ramos-Alvarez I, Jensen RT.

Front Endocrinol (Lausanne). 2018 Jun 29;9:345. doi: 10.3389/fendo.2018.00345. eCollection 2018. Review.

4.

Design, synthesis and biological evaluation of hybrid nitroxide-based non-steroidal anti-inflammatory drugs.

Thomas K, Moody TW, Jensen RT, Tong J, Rayner CL, Barnett NL, Fairfull-Smith KE, Ridnour LA, Wink DA, Bottle SE.

Eur J Med Chem. 2018 Mar 10;147:34-47. doi: 10.1016/j.ejmech.2018.01.077. Epub 2018 Jan 31.

PMID:
29421569
5.

A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.

Moreno P, Mantey SA, Lee SH, Ramos-Álvarez I, Moody TW, Jensen RT.

Peptides. 2018 Mar;101:213-226. doi: 10.1016/j.peptides.2018.01.016. Epub 2018 Feb 2.

6.

AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.

Moody TW, Tashakkori N, Mantey SA, Moreno P, Ramos-Alvarez I, Leopoldo M, Jensen RT.

Front Endocrinol (Lausanne). 2017 Jul 21;8:176. doi: 10.3389/fendo.2017.00176. eCollection 2017.

7.

Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.

Moody TW, Ramos-Alvarez I, Moreno P, Mantey SA, Ridnour L, Wink D, Jensen RT.

Peptides. 2017 Apr;90:90-99. doi: 10.1016/j.peptides.2017.01.012. Epub 2017 Jan 31.

8.

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Moreno P, Ramos-Álvarez I, Moody TW, Jensen RT.

Expert Opin Ther Targets. 2016 Sep;20(9):1055-73. doi: 10.1517/14728222.2016.1164694. Epub 2016 Mar 28. Review.

9.

The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies.

Smith JP, Fonkoua LK, Moody TW.

Int J Biol Sci. 2016 Jan 28;12(3):283-91. doi: 10.7150/ijbs.14952. eCollection 2016. Review.

10.

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Moody TW, Nuche-Berenguer B, Jensen RT.

Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):38-47. doi: 10.1097/MED.0000000000000218. Review.

11.

Insights into bombesin receptors and ligands: Highlighting recent advances.

Ramos-Álvarez I, Moreno P, Mantey SA, Nakamura T, Nuche-Berenguer B, Moody TW, Coy DH, Jensen RT.

Peptides. 2015 Oct;72:128-44. doi: 10.1016/j.peptides.2015.04.026. Epub 2015 May 11. Review.

12.

Neuropeptides as lung cancer growth factors.

Moody TW, Moreno P, Jensen RT.

Peptides. 2015 Oct;72:106-11. doi: 10.1016/j.peptides.2015.03.018. Epub 2015 Mar 30. Review.

PMID:
25836991
13.

CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Moody TW, Nuche-Berenguer B, Moreno P, Jensen RT.

J Mol Neurosci. 2015 Jul;56(3):663-72. doi: 10.1007/s12031-015-0533-6. Epub 2015 Mar 12.

14.

A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.

Ramos-Álvarez I, Mantey SA, Nakamura T, Nuche-Berenguer B, Moreno P, Moody TW, Maderdrut JL, Coy DH, Jensen RT.

Peptides. 2015 Apr;66:26-42. doi: 10.1016/j.peptides.2015.01.009. Epub 2015 Feb 16.

15.

EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.

Moody TW, Nuche-Berenguer B, Nakamura T, Jensen RT.

Curr Drug Targets. 2016;17(5):520-8. Review.

PMID:
25563590
16.

ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.

Moody TW, Mantey SA, Moreno P, Nakamura T, Lacivita E, Leopoldo M, Jensen RT.

Peptides. 2015 Feb;64:55-61. doi: 10.1016/j.peptides.2014.12.005. Epub 2014 Dec 30.

17.

SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.

Moody TW, Chan DC, Mantey SA, Moreno P, Jensen RT.

Life Sci. 2014 Mar 28;100(1):25-34. doi: 10.1016/j.lfs.2014.01.072. Epub 2014 Feb 2.

18.
19.

Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.

Moody TW, Osefo N, Nuche-Berenguer B, Ridnour L, Wink D, Jensen RT.

J Pharmacol Exp Ther. 2012 Jun;341(3):873-81. doi: 10.1124/jpet.111.190033. Epub 2012 Mar 2.

20.

Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.

Moody TW, Leyton J, Jensen RT.

J Mol Neurosci. 2012 Jan;46(1):68-74. doi: 10.1007/s12031-011-9639-7. Epub 2011 Sep 6.

PMID:
21898124
21.

Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.

Moody TW, Sancho V, di Florio A, Nuche-Berenguer B, Mantey S, Jensen RT.

Peptides. 2011 Aug;32(8):1677-84. doi: 10.1016/j.peptides.2011.06.011. Epub 2011 Jun 25.

22.

VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.

Moody TW, Ito T, Osefo N, Jensen RT.

Curr Opin Endocrinol Diabetes Obes. 2011 Feb;18(1):61-7. doi: 10.1097/MED.0b013e328342568a. Review.

23.

Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Sancho V, Di Florio A, Moody TW, Jensen RT.

Curr Drug Deliv. 2011 Jan;8(1):79-134. Review.

24.

Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Sancho V, Moody TW, Mantey SA, Di Florio A, Uehara H, Coy DH, Jensen RT.

Peptides. 2010 Aug;31(8):1569-78. doi: 10.1016/j.peptides.2010.04.023. Epub 2010 May 12.

25.

Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.

Moody TW, Berna MJ, Mantey S, Sancho V, Ridnour L, Wink DA, Chan D, Giaccone G, Jensen RT.

Eur J Pharmacol. 2010 Jul 10;637(1-3):38-45. doi: 10.1016/j.ejphar.2010.03.057. Epub 2010 Apr 11.

26.

Isolation, identification and biological activity of gastrin-releasing peptide 1-46 (oGRP 1-46), the primary GRP gene-derived peptide product of the pregnant ovine endometrium.

Giraud AS, Dumesny C, Whitley JC, Parker LM, Jennings I, Kemp B, Moody TW, Sancho V, Jensen RT, Shulkes A.

Peptides. 2010 Feb;31(2):284-90. doi: 10.1016/j.peptides.2009.11.013. Epub 2009 Nov 26.

27.

Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity.

Switzer CH, Ridnour LA, Cheng RY, Sparatore A, Del Soldato P, Moody TW, Vitek MP, Roberts DD, Wink DA.

Oncogene. 2009 Oct 29;28(43):3837-46. doi: 10.1038/onc.2009.244. Epub 2009 Aug 24.

28.

Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.

Moody TW, Switzer C, Santana-Flores W, Ridnour LA, Berna M, Thill M, Jensen RT, Sparatore A, Del Soldato P, Yeh GC, Roberts DD, Giaccone G, Wink DA.

Lung Cancer. 2010 May;68(2):154-60. doi: 10.1016/j.lungcan.2009.06.012. Epub 2009 Jul 23.

29.

Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.

González N, Mantey SA, Pradhan TK, Sancho V, Moody TW, Coy DH, Jensen RT.

Peptides. 2009 Aug;30(8):1473-86. doi: 10.1016/j.peptides.2009.05.007. Epub 2009 May 20.

30.

Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.

Bass SE, Sienkiewicz P, Macdonald CJ, Cheng RY, Sparatore A, Del Soldato P, Roberts DD, Moody TW, Wink DA, Yeh GC.

Clin Cancer Res. 2009 Mar 15;15(6):1964-72. doi: 10.1158/1078-0432.CCR-08-1870. Epub 2009 Mar 10.

31.

Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.

Moody TW, Pradhan T, Mantey SA, Jensen RT, Dyba M, Moody D, Tarasova NI, Michejda CJ.

Life Sci. 2008 Apr 9;82(15-16):855-61. doi: 10.1016/j.lfs.2008.01.019. Epub 2008 Feb 14.

32.

Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states.

Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT.

Curr Opin Endocrinol Diabetes Obes. 2008 Feb;15(1):58-64. doi: 10.1097/MED.0b013e3282f3709b. Review.

33.

Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.

Moody TW, Mantey SA, Fuselier JA, Coy DH, Jensen RT.

Peptides. 2007 Sep;28(9):1883-90. Epub 2007 May 6.

34.

Thymosin alpha1 as a chemopreventive agent in lung and breast cancer.

Moody TW.

Ann N Y Acad Sci. 2007 Sep;1112:297-304. Epub 2007 Jun 13.

PMID:
17567944
35.

Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer.

Moody TW, Gozes I.

Curr Pharm Des. 2007;13(11):1099-104. Review.

PMID:
17430173
36.

Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid.

Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, Sowers AL, Yeh GC, Moody TW, Wink DA, Ramchandran R, Roberts DD.

Br J Pharmacol. 2007 May;151(1):63-72. Epub 2007 Mar 12.

37.

Gastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism.

Hoffmann KM, Tapia JA, Berna MJ, Thill M, Braunschweig T, Mantey SA, Moody TW, Jensen RT.

J Biol Chem. 2006 Dec 8;281(49):37705-19. Epub 2006 Oct 10.

38.

Breast cancer VPAC1 receptors.

Moody TW, Jensen RT.

Ann N Y Acad Sci. 2006 Jul;1070:436-9.

PMID:
16888206
39.

In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.

Moody TW, Sun LC, Mantey SA, Pradhan T, Mackey LV, Gonzales N, Fuselier JA, Coy DH, Jensen RT.

J Pharmacol Exp Ther. 2006 Sep;318(3):1265-72. Epub 2006 Jun 9.

PMID:
16766720
40.

Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.

Moody TW, Nakagawa T, Kang Y, Jakowlew S, Chan D, Jensen RT.

J Mol Neurosci. 2006;28(3):231-8.

PMID:
16691010
41.

Peptide hormones and lung cancer.

Moody TW.

Panminerva Med. 2006 Mar;48(1):19-26. Review.

PMID:
16633328
42.

Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells.

Moody TW, Fuselier J, Coy DH, Mantey S, Pradhan T, Nakagawa T, Jensen RT.

Peptides. 2005 Sep;26(9):1560-6. Epub 2005 Apr 9.

PMID:
16112393
43.

Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.

Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J, Jensen RT.

Clin Cancer Res. 2005 May 1;11(9):3233-42.

44.

Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo.

Martínez A, Zudaire E, Julián M, Moody TW, Cuttitta F.

Oncogene. 2005 Jun 9;24(25):4106-13.

PMID:
15750618
45.

The development of VIP-ellipticine conjugates.

Moody TW, Czerwinski G, Tarasova NI, Moody DL, Michejda CJ.

Regul Pept. 2004 Dec 15;123(1-3):187-92.

PMID:
15518911
46.

Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.

You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM.

Oncogene. 2004 Aug 12;23(36):6170-4.

PMID:
15208662
47.
48.

Identification of vasoactive nonpeptidic positive and negative modulators of adrenomedullin using a neutralizing antibody-based screening strategy.

Martínez A, Julián M, Bregonzio C, Notari L, Moody TW, Cuttitta F.

Endocrinology. 2004 Aug;145(8):3858-65. Epub 2004 Apr 23.

PMID:
15107357
49.

Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells.

Moody TW, Mantey SA, Pradhan TK, Schumann M, Nakagawa T, Martinez A, Fuselier J, Coy DH, Jensen RT.

J Biol Chem. 2004 May 28;279(22):23580-9. Epub 2004 Mar 11.

50.

VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.

Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, Petricoin E, Couldrey C, Green JE.

Life Sci. 2004 Jan 30;74(11):1345-57.

PMID:
14706566

Supplemental Content

Loading ...
Support Center